GET DAILY SIGNALSIntensity Therapeutics (INTS) Reports Wider-Than-Expected Q3 Loss as Trials Resume
Key Takeaways
- Intensity Therapeutics reported a third-quarter 2026 net loss of $1.09 per share, wider than the roughly $0.94–$0.99 per-share loss analysts had expected.
- The company's net loss widened to $3.5 million from $2.7 million a year earlier, driven primarily by higher research and development (R&D) spending tied to resumed clinical trial activity.
- Revenue remained at zero, consistent with the company's status as a pre-revenue, clinical-stage biotechnology firm.
- Cash and cash equivalents declined to $8.5 million at quarter-end, from $9.5 million at the end of June, underscoring ongoing funding needs.
- Enrollment resumed in the Phase 3 INVINCIBLE-3 soft tissue sarcoma trial and in the INVINCIBLE-4 triple-negative breast cancer (TNBC) study.
- Management reaffirmed cash-burn guidance of roughly $1 million per month for the fourth quarter but did not provide a 2027 outlook.
Understanding the Earnings Context
Intensity Therapeutics is a late-stage clinical biotechnology company developing INT230-6, an intratumoral therapy designed to kill cancer cells locally while triggering a systemic immune response. Because the company has no commercial products, its quarterly results are driven almost entirely by spending rather than sales. As a result, investors focus less on profit figures and more on cash runway, clinical progress, and trial timelines. The third quarter marked a pivotal moment: after an extended pause, the company resumed patient enrollment in its lead Phase 3 soft tissue sarcoma program and advanced its TNBC study. With cash finite, the pace of spending and the ability to secure additional funding now carry outsized weight for the stock's trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
Intensity Therapeutics reported a third-quarter 2026 net loss of $1.09 per share, missing consensus estimates of roughly $0.94 to $0.99 per share. The absolute net loss widened to $3.5 million from $2.7 million in the prior-year period. While the per-share figure narrowed from $1.55 a year ago, that improvement was largely a function of a higher weighted share count, which nearly doubled to 3.26 million shares, rather than a reduction in overall losses. Revenue was zero, as expected for a pre-revenue company.
Spending was the central story. R&D expense rose to $2.4 million from $1.6 million a year earlier, reflecting restarted INVINCIBLE-3 site activity, a new INT230-6 manufacturing batch, higher stock-based compensation, and a bonus accrual. General and administrative expense was roughly flat at $1.2 million. Cash declined to $8.5 million at quarter-end from $9.5 million at the end of June and $11.9 million at the start of the year. The company raised about $1.5 million net through its at-the-market offering facility during the quarter, with a further $1.3 million raised after quarter-end.
Market Reaction and Investor Sentiment
Investor sentiment had improved heading into the report, but the stock's reaction was less enthusiastic. Shares closed at $3.50 before the announcement, already down from the $4.17 open that followed the company's August update. On the day of the release, the stock traded sharply lower, reflecting concerns about the wider-than-expected loss and the company's shrinking cash balance. For a pre-revenue biotech, the market tends to price in the gap between clinical progress and available funding, and the third-quarter results sharpened that focus. While resumed enrollment and encouraging early INVINCIBLE-4 data offered positive signals, the absence of a 2027 financial outlook and a cash position measured in months left investors weighing near-term dilution risk against long-term pipeline potential.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important factor for INTS is capital. Management reaffirmed a cash-burn guide of roughly $1 million per month for the fourth quarter of 2026, but offered no full-year 2027 outlook. At those rates, the company holds well under a year of runway, and executives have explicitly linked the pace of trial-site expansion to obtaining sufficient incremental funding. Investors should watch for signs of additional financing, whether through the ATM facility, partnerships, or other means.
Clinical execution will also matter. In the Phase 3 INVINCIBLE-3 sarcoma study, several U.S. sites are now active with patients in screening, and the company has submitted restart filings in the European Union and Canada, with EU approval expected in the first quarter of 2027. For INVINCIBLE-4 in TNBC, an independent data monitoring board is expected to confirm in early 2027 whether a skin-irritation issue has been resolved. Early efficacy data — a 71% pathological complete response rate versus 42% for standard of care — are encouraging but based on a small sample of 14 patients.
Finally, business development remains a potential catalyst. Partnering discussions have advanced from introductory meetings to confidentiality agreements and data-room access with several multinational and regional players. Any material collaboration or licensing agreement could reshape the funding picture and reduce dilution risk for existing shareholders. From what I see, this is important because it could ease the funding pressure that currently dominates the story.
AI Tools in My Research Process
I regularly turn to Tickeron’s AI Screener when evaluating clinical-stage names like this one. It helps me quickly compare peers on fundamentals, technical patterns, and AI signals, which adds useful context to the quarterly numbers and trial updates without replacing my own analysis of the cash position and enrollment progress.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INTS in +4.92% Uptrend, growing for three consecutive days on November 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INTS advanced for three days, in 101 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INTS's RSI Indicator exited the oversold zone, 20 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on INTS as a result. In 37 of 58 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for INTS just turned positive on October 28, 2026. Looking at past instances where INTS's MACD turned positive, the stock continued to rise in 20 of 31 cases over the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
INTS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INTS entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.098) is normal, around the industry mean (2.904). P/E Ratio (-1.550) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. INTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement